Table 2.
Number and proportion of patients with Hb at different levels in the 2 roxadustat dose groups
| Time point | Hb (g/dl) | Standard-dose group n (%) | Low-dose group n (%) | Pa |
|---|---|---|---|---|
| Baseline | ||||
| <100 | 7 (14.0) | 7 (14.0) | 1.00 | |
| ≥100 and ≤120 | 43 (86) | 43 (86) | 1.00 | |
| >120 | 0 (0) | 0 (0) | — | |
| Week 2 | ||||
| <100 | 4 (8) | 10 (20) | 0.08 | |
| ≥100 and ≤120 | 38 (76) | 36 (72) | 0.65 | |
| >120 | 8 (16) | 4 (8) | 0.22 | |
| >130 | 2(4) | 1(2) | 0.56 | |
| Week 4 | ||||
| <100 | 4 (8) | 9 (18) | 0.14 | |
| ≥100 and ≤120 | 28 (56) | 29 (58) | 0.84 | |
| >120 | 18 (36) | 12 (24) | 0.19 | |
| >130 | 5(10) | 3(6) | 0.46 | |
| Week 8 | ||||
| <100 | 2 (4) | 10 (20) | 0.01 | |
| ≥100&≤120 | 33 (66) | 23 (46) | 0.04 | |
| >120 | 15 (30) | 17 (34) | 0.67 | |
| >130 | 5(10) | 6(12) | 0.75 | |
| Week 12 | ||||
| <100 | 3 (6) | 10 (20) | 0.04 | |
| ≥100 and ≤120 | 31 (62) | 26 (52) | 0.31 | |
| >120 | 16 (32) | 14 (28) | 0.66 | |
| >130 | 2(4) | 5(10) | 0.24 |
Hb, hemoglobin.
a
At each time point, comparisons between groups were performed at each category of Hb level range by 2 × 2 crosstabs.